But the response to ICI is varied in patients with lung cancer; especially, some patients do not respond to anti-PD-1/PD-L1 immunotherapy accompanied by toxic side effects, which lead to discontinuation ICI and switch to the other therapies. This evidence concerns the gene PDCD1 and lung cancer.